Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide

Biochemical and Biophysical Research Communications

Volumn 413, Issue 2, 2011, Pages 383-388

  Chen, Zhengming ^a   Zhou, Jun ^a   Zhang, Yingtao ^a   Bepler, Gerold ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Gemcitabine; N ethylmaleimide; RRM1

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; METHOTREXATE; N ETHYLMALEIMIDE; NAVELBINE; PEMETREXED; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; ENZYME STABILITY; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOMARKERS, PHARMACOLOGICAL; CATALYTIC DOMAIN; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETHYLMALEIMIDE; HUMANS; MICE; MICE, INBRED STRAINS; PROTEIN CONFORMATION; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 80053122905     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.111     Document Type: Article

References (26)

1. Reichard P. From RNA to DNA, why so many ribonucleotide reductases?. Science 1993, 260:1773-1777.
2. Stubbe J., van der Donk W.A. Ribonucleotide reductases: radical enzymes with suicidal tendencies. Chem. Biol. 1995, 2:793-801.
3. Fan H., Huang A., Villegas C., Wright J.A. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc. Natl. Acad. Sci. USA 1997, 94:13181-13186.
4. Gautam A., Li Z.R., Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 2003, 22:2135-2142.
5. Gautam A., Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res. 2006, 66:6497-6502.
6. Kashlan O.B., Cooperman B.S. Comprehensive model for allosteric regulation of mammalian ribonucleotide reductase: refinements and consequences. Biochemistry 2003, 42:1696-1706.
7. Persson A.L., Eriksson M., Katterle B., Potsch S., Sahlin M., Sjoberg B.M. A new mechanism-based radical intermediate in a mutant R1 protein affecting the catalytically essential Glu441 in Escherichia coli ribonucleotide reductase. J. Biol. Chem. 1997, 272:31533-31541.
8. Kasrayan A., Persson A.L., Sahlin M., Sjoberg B.M. The conserved active site asparagine in class I ribonucleotide reductase is essential for catalysis. J. Biol. Chem. 2002, 277:5749-5755.
9. Mao S.S., Holler T.P., Yu G.X., Bollinger J.M., Booker S., Johnston M.I., Stubbe J. A model for the role of multiple cysteine residues involved in ribonucleotide reduction: amazing and still confusing. Biochemistry 1992, 31:9733-9743.
10. Rosell R., Danenberg K., Alberola V., Bepler G., Sanchez J.J., Camps C., Provencio M., Isla D., Taron M., Diz P., Artal A. Ribonucleotide reductase mRNA expression and survival in gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin. Cancer Res. 2004, 10:1318-1325.
11. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., Simon G. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 2006, 24:4731-4737.
12. Akita H., Zheng Z., Takeda Y., Chiwan K., Kittaka N., Kobayashi S., Marubashi S., Takemasa I., Nagano H., Dono K., Nkamori S., Monden M., Mori M., Doki Y., Bepler G. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009, 28:2903-2909.
13. Bepler G., Sharma S., Cantor A., Gautam A., Haura E., Simon G., Sharma A., Sommers E., Robinson L. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 2004, 22:1878-1885.
14. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler G. The DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 2007, 356:800-808.
15. Danesi R., Altavilla G., Giovannetti E., Rosell R. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics 2009, 10:69-80.
16. Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine: preclinical pharmacology and mechanism of action. Semin. Oncol. 1996, 23:3-15.
17. Pereira S., Fernandez P.A., Ramos M.J. Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine. J. Comput. Chem. 2004, 25:1286-1294.
18. Lohman G.J., Stubbe J. Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modification. Biochemistry 2010, 49:1404-1417.
19. Artin E., Wang J., Lohman G.J., Yokoyama K., Yu G., Griffin R.G., Bar G., Stubbe J. Insight into the mechanism of inactivation of ribonucleotide reductase by gemcitabine 5'-diphosphate in the presence or absence of reductant. Biochemistry 2009, 48:11622-11629.
20. Wang J., Lohman G.J., Stubbe J. Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibits ribonucleotide reductases. Proc. Natl. Acad. Sci. USA 2007, 104:14324-14329.
21. Smyth D.G., Blumenfeld O.O., Konigsberg W. Reactions of N-ethylmaleimide with peptides and amino acids. Biochem. J. 1964, 91:589-595.
22. Yellaturu C.R., Bhanoori M., Neeli I., Rao G.N. N-Ethylmaleimide inhibits platelet-derived growth factor BB-stimulated Akt phosphorylation via activation of protein phosphatase 2A. J. Biol. Chem. 2002, 277:40148-40155.
23. Humphries K.M., Deal M.S., Taylor S.S. Enhanced dephosphorylation of cAMP-dependent protein kinase by oxidation and thiol modification. J. Biol. Chem. 2005, 280:2750-2758.
24. Wang J., Lohman G.J., Stubbe J. Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate. Biochemistry 2009, 48:11612-11621.
25. Lohman G.J., Gerfen G.J., Stubbe J. Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: adenosylcobalamin destruction and formation of a neucleotide-based radical. Biochemistry 2010, 49:1396-1403.
26. Erickson H.K. Formation of the cystine between cysteine 225 and cysteine 462 from ribonucleoside diphosphate reductase is kinetically competent. Biochemistry 2000, 39:9241-9250.